TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28389801
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous analgesia with fentanyl (IV PCA group)
Study: 26268910
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg CCX140-B
Study: 26268910
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg CCX140-B
Study: 24157585
Drug: Slow intravenous
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow intravenous injection of photosensitizer during the first 15 minutes of irradiation (Group A)
Study: 24157585
Drug: Fomentation before
Normalized name: Cacao seed oil, fermented
DrugBank: Cocoa butter (DB11086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fomentation before photosensitizer injection and irradiation (Group B)
Study: 24157585
Drug: Traditional injection
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional injection method (Control Group C)
Study: 11561779
Drug: High-dose etoposide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose etoposide (3 x 400 mg/m2)
Study: 9243169
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate (CIT) at a dose of 0.5 g.kg‐1 body mass
Study: 8488172
Drug: DL-cysteine 200
Normalized name: CYSTEINE, DL-
Approvals — FDA: no, EMA: no, PMDA: no
Description: DL-cysteine 200 mg 4 times daily
Study: 8488172
Drug: DL-methionine-methyl sulphonium
Normalized name: N-acetyl-methionine, DL-
Approvals — FDA: no, EMA: no, PMDA: no
Description: DL-methionine-methyl sulphonium chloride (MMSC) 500 mg 4 times daily
Study: 3552683
Drug: High-dose IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IV Metoclopramide (1 mg/kg/dose X 5 doses)
Study: 3552683
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Metoclopramide (same schedule) plus Nortriptyline (50 mg PO X 2 doses) plus Thiethylperazine (10 mg IV X 3 doses)
Study: 27477773
Drug: Statin-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin-based therapy
Study: 25137523
Drug: Hot saline
Normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hot saline irrigation (HSI) at 49°C, 20 mL every 10 minutes during FESS
Study: 25137523
Drug: Room temperature
Normalized name: ROOM DEODORIZER POWDER MENTOR #3202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room temperature saline irrigation (RTSI) at 18°C, 20 mL every 10 minutes during FESS
Study: 23869107
Drug: Butylscopolamine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butylscopolamine 20 mg i.v.
Study: 19115656
Drug: 36 ml
Normalized name: ALCOHOL 177 mL in 236 mL TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 ml of levobupivacaine 0.1%
Study: 19115656
Drug: 72 ml
Normalized name: ethanol 0.72 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 72 ml of levobupivacaine 0.1%
Study: 19115656
Drug: 36 ml
Normalized name: ALCOHOL 177 mL in 236 mL TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 ml of levobupivacaine 0.25%
Study: 8970819
Drug: Aspirin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (3 x 320 mg capsules every 6 h for 3 days, total 3.84 g/day)
Study: 8509313
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical schedule as aspirin)
Study: 2868900
Drug: endralazine 5
Normalized name: hydralazine hydrochloride 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: endralazine 5 mg
Study: 29748932
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 or 1000 mg twice daily for 37 weeks
Study: 29748932
Drug: Metformin in
Normalized name: Product containing metformin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin in obese adolescents
Study: 27647769
Drug: AbobotulinumtoxinA (ABO)
Normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: AbobotulinumtoxinA (ABO) intradermal injection at 1:7 cc dilution (500 unit in 7 cc of NSS)
Study: 27647769
Drug: AbobotulinumtoxinA (ABO)
Normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: AbobotulinumtoxinA (ABO) intradermal injection
Study: 22886431
Drug: Diode laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diode laser treatment at fluences of 7 J/cm²
Study: 22886431
Drug: Diode laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diode laser treatment at fluences of 12 J/cm²
Study: 22886431
Drug: Diode laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diode laser treatment at fluences of 20 J/cm²
Study: 20942239
Drug: Bronchial lavage
Normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bronchial lavage (BL) with 1% lidocaine (2 ml) and 0.125% metronidazole (5 ml) during bronchoscopic procedure
Study: 18307585
Drug: Antipsychotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic treatment (Olanzapine, Risperidone, Haloperidol)
Study: 12418584
Drug: Post-bronchodilator values
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-bronchodilator values
Study: 2297337
Drug: Test drug
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug in one eye
Study: 101843
Drug: Four-drug combination
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-drug combination (hexamethylmelamine, cyclophosphamide, methotrexate, 5-fluorouracil)
Study: 30761945
Drug: Move-A-Thon (MAT)
Normalized name: thonzonium
DrugBank: Thonzonium (DB09552)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Move-A-Thon (MAT) event with monetized donations to charity, incentivizing participants to achieve a minimum of 3,000 daily steps for 2 weeks.
Study: 8866933
Drug: ORG 2766
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORG 2766 (40 mg for 6 weeks)
Study: 6509234
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of two-hourly toileting for five weeks and environmental changes (Ward B)
Study: 26667449
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg QD
Study: 26667449
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg Q-MWF
Study: 26667449
Drug: Letrozole 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 1.0 mg Q-MWF
Study: 26667449
Drug: Letrozole 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 0.25 mg Q-MWF
Study: 26667449
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard dose arm)
Study: 26667449
Drug: All dose
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dose arms
Study: 22487197
Drug: Adolescents and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adolescents and adults (young, middle-aged, and older) with 25(OH)D levels ≤50 nmol/L in winter/spring
Study: 22487197
Drug: Adolescents and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adolescents and adults (young, middle-aged, and older) with 25(OH)D levels ≤25 nmol/L in winter/spring
Study: 22487197
Drug: Primary schoolchildren
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary schoolchildren with 25(OH)D levels <50 nmol/L
Study: 22487197
Drug: Primary schoolchildren
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary schoolchildren with 25(OH)D levels ≤25 nmol/L
Study: 22487197
Drug: Adolescents and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adolescents and adults with 25(OH)D levels ≤50 nmol/L in summer/autumn
Study: 22487197
Drug: Adolescents and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adolescents and adults with 25(OH)D levels ≤25 nmol/L in summer/autumn
Study: 20737278
Drug: Local warming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local warming at injection site using an air‐warming device at 40°C for 1 minute prior to injecting 1 ml (10 mg) of rocuronium.
Study: 20737278
Drug: Local warming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local warming at injection site.
Study: 18614726
Drug: F+0 (control)
Normalized name: F
Approvals — FDA: no, EMA: no, PMDA: no
Description: F+0 (control) - 6 microg Se/L
Study: 18614726
Drug: F+7 -
Normalized name: F
Approvals — FDA: no, EMA: no, PMDA: no
Description: F+7 - 13 microg Se/L
Study: 18614726
Drug: F+15 -
Normalized name: F
Approvals — FDA: no, EMA: no, PMDA: no
Description: F+15 - 21 microg Se/L
Study: 18614726
Drug: BF -
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BF - breastfed reference group (11 +/- 2 microg Se/L)
Study: 12368787
Drug: Subacromial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subacromial injection of a mixture of 0.5 mL (2.5 mg) betamethasone acetate and 3 mL of radiographic contrast material (iotrolan) and 7 mL of 1% lidocaine
Study: 12368787
Drug: Intradeltoid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradeltoid injection
Study: 7745355
Drug: Ifenprodil tartrate
Normalized name: ifenprodil tartrate
DrugBank: Ifenprodil (DB08954)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifenprodil tartrate (60 mg a.d.)
Study: 2292326
Drug: sobrerol granules
Normalized name: sobrerol
DrugBank: Sobrerol (DB13315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sobrerol granules 900 mg/day for up to 10 days
Study: 29317414
Drug: Virtual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual therapy (VT) for 8 weeks, performing 3-5 upper limb exercises individualized to impairment severity and preference
Study: 29317414
Drug: Virtual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual therapy (VT) for 8 weeks
Study: 27440543
Drug: 3.4 g
Normalized name: psyllium 3.4 g oral wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.4 g PS esters-enriched soy milk powder (2.0 g/d free PS in 30 g soy milk powder)
Study: 20409444
Drug: Antidepressant continuation
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant continuation
Study: 10717833
Drug: Regimen A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A: 100 mg/m2 i.a. cisplatin followed by 5 day continuous intravenous infusion of 5‐fluorouracil (1 g/m2 per day)
Study: 10717833
Drug: Regimen B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B: i.a. high pressure chemo‐perfusion with 150 mg/m2 cisplatin and simultaneous intravenous infusion of 9 g/m2 sodium thiosulfate
Study: 7025875
Drug: Extradural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural morphine (10 mg)
Study: 19994615
Drug: I-gel Supraglottic
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-gel Supraglottic Airway (IGSA)
Study: 19994615
Drug: Supreme Laryngeal
Normalized name: Supreme
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supreme Laryngeal Mask Airway (SLMA) and I-gel Supraglottic Airway (IGSA)
Study: 17885010
Drug: Soy germ
Normalized name: soy germ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy germ pasta (80-g serving/d)
Study: 15166388
Drug: Perindopril 4
Normalized name: perindopril 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 4 mg daily for 2 weeks
Study: 9506196
Drug: ADCON-L gel
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADCON-L gel
Study: 9479681
Drug: Clinician-Administered Dissociative
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician-Administered Dissociative States Scale (CADSS)
Study: 17034278
Drug: Homeopathic combination
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic combination therapy
Study: 14647086
Drug: 667 mg
Normalized name: tryptophan 667 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 667 mg encapsulated sucralose daily for 13 weeks
Study: 14647086
Drug: Placebo (cellulose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cellulose) capsules daily for 13 weeks
Study: 8949786
Drug: Lomefloxacin 400
Normalized name: lomefloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomefloxacin 400 mg once a day for three days
Study: 8949786
Drug: Pefloxacin 800
Normalized name: pefloxacin
DrugBank: Pefloxacin (DB00487)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin 800 mg once a day for three days
Study: 2224374
Drug: Buspirone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (5 mg t.d.s.)
Study: 30081698
Drug: Topical tazarotene
Normalized name: tazarotene Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tazarotene 0.1% after fractional CO2 laser treatment
Study: 30081698
Drug: Topical tioconazole
Normalized name: tioconazole Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tioconazole 28% after fractional CO2 laser treatment
Study: 30081698
Drug: KOH test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: KOH test and culture results after treatment in Group A
Study: 30081698
Drug: KOH test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: KOH test and culture results after treatment in Group B
Study: 27987182
Drug: Supervised modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised modified step aerobics training (twice weekly, 1 hour per session) over a period of 6 months
Study: 24727345
Drug: 2-week group-based
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week group-based multicomponent treatment course
Study: 22410382
Drug: Dexamethasone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (5 mg daily for 4 days)
Study: 19588641
Drug: Tretinoin microsphere
Normalized name: tretinoin microsphere
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin microsphere gel pump 0.04% (TMG PUMP)
Study: 19588641
Drug: Tazarotene cream
Normalized name: Tazarotene Cream
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene cream 0.05% (TAZ)
Study: 17616006
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg grape seed extract (calculated as proanthocyanidin)
Study: 17616006
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg grape seed extract (calculated as proanthocyanidin)
Study: 3675134
Drug: mCPP (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: mCPP (0.5 mg/kg, orally)
Study: 21915733
Drug: Cefotetan disodium
Normalized name: Cefotetan Disodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan disodium 0.5 g
Study: 21915733
Drug: Cefotetan disodium
Normalized name: Cefotetan Disodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan disodium 2.0 g
Study: 23901678
Drug: Cinitapride 1mg
Normalized name: cinitapride
DrugBank: Cinitapride (DB08810)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinitapride 1mg thrice daily 15 minutes before meals for 4 weeks
Study: 19968382
Drug: Beginning therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beginning therapy alliance (after Session 1)
Study: 19968382
Drug: Clients' beginning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clients' beginning therapy process
Study: 11472271
Drug: Insulin analogues
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin analogues (general)
Study: 3115841
Drug: L-lysine monohydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-lysine monohydrochloride (1,000 mg per dose, 3 times a day for 6 months)
Study: 25039273
Drug: LY3000328 (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3000328 (up to 300 mg)
Study: 22503610
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II receptor blocker + calcium channel blocker
Study: 22503610
Drug: High-dose angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose angiotensin II receptor blocker (40 mg/d olmesartan)
Study: 19459794
Drug: MMF(CC) and
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF(CC) and reduced-level calcineurin inhibitor (MMF(CC)/CNI(RL))
Study: 19459794
Drug: MMF(CC) and
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF(CC) and standard-level CNI (MMF(CC)/CNI(SL))
Study: 19459794
Drug: fixed-dose MMF
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fixed-dose MMF and CNI(SL) (MMF(FD)/CNI(SL))
Study: 11476427
Drug: Subcutaneous fat
Normalized name: Sus scrofa subcutaneous fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous fat increase in girls during puberty
Study: 11476427
Drug: VO2peak expressed
Approvals — FDA: no, EMA: no, PMDA: no
Description: VO2peak expressed as ml kg(‐1) min(‐1)
Study: 7932683
Drug: Treatment subjects
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment subjects
Study: 29883885
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of intravenous paracetamol every 4 h for 72 h
Study: 27841759
Drug: Sufficient vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufficient vitamin D status (25OHD ≥30 ng/ml)
Study: 20585969
Drug: Single-dose fosfomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose fosfomycin trometamol (FMT) 3 g
Study: 20585969
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg twice a day for 5 days
Study: 16323126
Drug: Antimalarial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimalarial treatment (specific regimens not detailed)
Study: 15456051
Drug: Passive transverse
Normalized name: TRANSVERSE ROD,STERILE COLOPLAST #2919
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive transverse forces (PTF) applied on the deformed body, 4 to 6 treatments lasting 20 minutes each, combined with intensive rehabilitation.
Study: 15456051
Drug: PTF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTF treatment without additional braces (n=52).
Study: 7197959
Drug: Urapidil (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil (2 times 25 mg)
Study: 7197959
Drug: Phentolamine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine (2 times 5 mg)
Study: 26408012
Drug: High-dose intensity-modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intensity-modulated radiation therapy (IMRT) combined with androgen deprivation therapy (ADT) for 6 months
Study: 16206677
Drug: Oxymatrine (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymatrine (intravenous or intra-muscular injection and oral capsule)
Study: 9872196
Drug: Salbutamol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (200 microg by metered‐dose inhaler)
Study: 7884169
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (tripotassium dicitrato bismuthate 125 mg q.i.d., tetracycline hydrochloride 500 mg q.i.d., metronidazole 500 mg t.i.d.)
Study: 344157
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg four times daily
Study: 25120315
Drug: Sirolimus (SRL)
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus (SRL) conversion from calcineurin inhibitors (CNI)
Study: 23194491
Drug: Paricalcitol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paricalcitol (2 μg oral)
Study: 20184605
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) for grass pollen; specific details on dosage and duration not provided.
Study: 20184605
Drug: Placebo treatment;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment; specific details on dosage and duration not provided.
Study: 15785883
Drug: Cefoxitin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (100 mg) added to Tisseel-VH fibrin sealant
Study: 15785883
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Cefoxitin + Surgical closure)
Study: 14728086
Drug: Oral ziprasidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ziprasidone
Study: 10532523
Drug: Nitroglycerin lingual
Normalized name: Nitroglycerin Lingual Spray
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin lingual spray
Study: 10532523
Drug: Nitroglycerin sublingual
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin sublingual tablet
Study: 1909749
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (TN)
Study: 1909749
Drug: Long-acting oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting oral nitrates (LAON)
Study: 3859027
Drug: Preventive measures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive measures focused on oral hygiene and/or fluorides
Study: 31118485
Drug: 3-month intervention
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month intervention involving a face-to-face meeting (medication review and consumer-centred video) and health coaching every two weeks
Study: 27416546
Drug: Topical furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical furosemide (300 µg per day, 2 puffs twice a day for 2 months)
Study: 20493474
Drug: 17β‐E2 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17β‐E2 1 mg/drospirenone 2 mg
Study: 20493474
Drug: 17β‐E2 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17β‐E2 1 mg/norethisterone acetate 0.5 mg
Study: 15616757
Drug: I.M. testovirone
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.M. testovirone depot 100 mg monthly for 6 months
Study: 15616757
Drug: Oxandrolone 5
Normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxandrolone 5 mg/m2 daily for 6 months